Vermillion this week appointed Bruce Huebner to its board of directors.
Currently Huebner is managing director at the healthcare consulting firm LynxCom Partners. Previously he was president and CEO of microarray company Nanogen, and before that he was executive vice president and chief operating officer of Gen-Probe.
Stacey Sias has left her positions at Celera as senior VP of business development and strategic planning and as an executive director, the company said in a recent filing with the US Securities and Exchange Commission.
Sias previously was VP of licensing at Roche Molecular Systems, she was a molecular biologist at Codon and Genentech, and she is a registered patent agent with the US Patent and Trademark Office.